Ocera Therapeutics (OCRX)
A total of 10 insiders (including 10% owners) made buys into Ocera Therapeutics this week as the company finalized its merger with Tranzyme. These buys were made at its combined offering price of $6.03 per share. The insiders bought a total of 9,510,586 shares of the newly combined companies’ stock.
Ocera is a clinical stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for patients with acute and chronic liver disease, an area of high unmet medical need.
Ocera Therapeutics’ historical price, revenue and net income:
[ Enlarge Image ]
On July 15 Ocera announced the completion of its merger with Tranzyme. The now merged company goes by Ocera Therapeutics and is traded under the Nasdaq Global Market under the symbol “OCRX.” The combined company now operates under the leadership of Linda Grais MD, president and CEO, and the board of directors consists of representatives from both the former Ocera and Tranzyme boards.
“The closing of this merger represents an important milestone as Ocera joins forces with Tranzyme to develop OCR-002, a differentiated product candidate for orphan liver diseases," said Dr. Grais.
Following the merger, the reverse split and the financing, the company has approximately 11.3 million shares outstanding.
Ocera has a market cap of $17.9 million; its shares were traded at around $10.30 with a P/S ratio of 3.50.
Walgreen Company (WAG)
Director Stefano Pessina made a significant buy into Walgreen last week. On July 12 the director bought 34,439 shares at an average price of $45.77 per share. This transaction cost the director a total of $1,576,273. Since his buy, the price per share has increased approximately 10.23%. Pessina currently holds more than 75 million shares of Walgreen Company.
Pessina also made a significant buy in April when he purchased 83,300 shares of company stock.
Pessina is the first insider making buys since 2010.
Walgreens is the nation’s largest drugstore chain with fiscal 2012 sales of $72 billion. Walgreen's scope of pharmacy services includes retail, specialty, infusion, medical facility and mail service, along with respiratory services. These services improve health outcomes and lower costs for payers including employers, managed care organizations, health systems, pharmacy benefit managers and the public sector.
Walgreens historical price, revenue and net income:
[ Enlarge Image ]
On July 10, Walgreen increased its shareholder payout by 14.5% by upping its quarterly cash dividend to $0.315 per share. Walgreen has paid a dividend in 232 consecutive quarters, spanning over 80 years. Over the past five years, Walgreen's annual dividend has increased from $0.45 to $1.26 per share, resulting in a compound annual growth rate of approximately 23%.
Walgreen is currently sitting near its 52-week and 10-year high price of $50.90.
Walgreen has a market cap of $46.95 billion. Its shares are currently being traded at around $50.49 with a P/E ratio of 22.10, a P/S ratio of 0.70 and a P/B ratio of 2.20. The company had an annual average earnings growth of 11.2% over the past ten years. GuruFocus rated Walgreen the business predictability rank of 4-star.
Terreno Realty (TRNO)
Four insiders made significant buys into Terreno Realty Corp. (TRNO) yesterday. These insider buys come as the company finished up its public offering of 5 million shares of common stock at a price of $18.25 per share. Today the price is trading up 5.81% from the public offering price.
President Michael Coke added 3,000 shares to his stake. This cost him a total of $54,750. Coke now owns a total of 184,000 shares of Terreno.
Chairman and CEO Blake Baird made the largest buy of the week. The CEO added 21,000 shares to his stake in Terreno for a total transaction amount of $383,250. Baird now owns a total of 436,807 shares of company stock.
CFO Jamie Jackson purchased 1,000 shares of Terreno during the public offering. This cost the CFO a total of $18,250. Jackson now owns a total of at least 39,082 shares of company stock.
Director LeRoy Carlson purchased 5,000 shares during the company’s public offering. This cost the director a total of $91,250. Carlson now owns at least 33,870 shares of Terreno Realty stock.
Terreno acquires, owns and operates industrial real estate in six major U.S. coastal markets where the nation’s largest consumer populations meet the highest-volume distribution points. The company owns 80 buildings and 6.1 million square feet in Los Angeles, Northern New Jersey/New York City, San Francisco Bay Area, Seattle, Miami and Washington, D.C./Baltimore.
Terreno’s historical price, revenue and net income:
[ Enlarge Image ]
The company recently released its quarterly investment and operating activities report which noted $61.6 million of acquisitions comprising 869,000 square feet and quarter end occupancy of 89.1% compared to prior year of 91.3%.
Terreno has a market cap of $364.8 million. Its shares are currently being traded at around $19.40 with a P/E ratio of 756.20, a P/S ratio of 7.60 and a P/B ratio of 0.80. The dividend yield for Terreno stocks is 2.5%.
You can view all insider buys at 52-week lows by using the GuruFocus All-in-One Screener.
Try a free 7-day GuruFocus Premium Membership here!
- CEO Buys, CFO Buys: Stocks that are bought by their CEO/CFOs.
- Insider Cluster Buys: Stocks that multiple company officers and directors have bought.
- Double Buys:: Companies that both Gurus and Insiders are buying
- Triple Buys: Companies that both Gurus and Insiders are buying, and Company is buying back.